Cargando…

Specific inhibitor of Notch-3 enhances the sensitivity of NSCLC cells to gemcitabine

Notch-3 is a receptor of the Notch signaling pathway and plays an important role in regulating self-renewal, differentiation and apoptosis in cancer cells. Overexpression of Notch-3 has been proved to be associated with resistance to gemcitabine (GEM) and poor patient prognosis for various malignant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Bi-Dan, Guo, Jia, Ye, Yuan-Zi, Du, Ting, Cheng, Chun-Song, Jiang, Qian, Liu, Ruo-Nan, Zhang, Yan-Bei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059738/ https://www.ncbi.nlm.nih.gov/pubmed/29781034 http://dx.doi.org/10.3892/or.2018.6448

Ejemplares similares

Synergistic Effect of Notch-3-Specific Inhibition and Paclitaxel in Non-Small Cell Lung Cancer (NSCLC) Cells Via Activation of The Intrinsic Apoptosis Pathway
por: He, Fenglian, et al.
Publicado: (2017)

Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC
por: Hu, Rong, et al.
Publicado: (2020)

The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC
por: Li, Xiaohua, et al.
Publicado: (2021)

Interferon regulatory factor 4 (IRF4) is overexpressed in human non-small cell lung cancer (NSCLC) and activates the Notch signaling pathway
por: Qian, Yajuan, et al.
Publicado: (2017)

Zinc oxide nanoparticles (ZnO NPs) combined with cisplatin and gemcitabine inhibits tumor activity of NSCLC cells
por: Hu, Chenping, et al.
Publicado: (2020)

Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
por: Blaauboer, Amber, et al.
Publicado: (2020)

RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC
por: Wang, Qian, et al.
Publicado: (2023)

Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine
por: Goss, Kelli L, et al.
Publicado: (2017)

Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer
por: Zoli, W, et al.
Publicado: (1999)

Angiogenesis Inhibitors in NSCLC
por: Manzo, Anna, et al.
Publicado: (2017)

Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine
por: Dai, Chun-Hua, et al.
Publicado: (2017)

CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine
por: Xu, Peng, et al.
Publicado: (2016)

Novel structured ADAM17 small-molecule inhibitor represses ADAM17/Notch pathway activation and the NSCLC cells’ resistance to anti-tumour drugs
por: Chi, Meng, et al.
Publicado: (2023)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components
por: Hsu, Sheng-Kai, et al.
Publicado: (2022)

The effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages
por: Wu, Yingcheng, et al.
Publicado: (2017)

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
por: An, Fengxiao, et al.
Publicado: (2023)

Co-Occurring Alteration of NOTCH and DDR Pathways Serves as Novel Predictor to Efficacious Immunotherapy in NSCLC
por: Zhang, Zhimin, et al.
Publicado: (2021)

Inhibition of JNK-mediated autophagy enhances NSCLC cell sensitivity to mTORC1/2 inhibitors
por: Jin, Hyeon-Ok, et al.
Publicado: (2016)

Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine
por: Li, Hua, et al.
Publicado: (2017)

ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner
por: Pan, Yi-Ru, et al.
Publicado: (2020)

Inactivation of XPF Sensitizes Cancer Cells to Gemcitabine
por: George, Joseph W., et al.
Publicado: (2019)

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
por: Helbekkmo, N, et al.
Publicado: (2007)

Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways
por: Schniewind, Bodo, et al.
Publicado: (2006)

Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine
por: Yin, Tao, et al.
Publicado: (2016)

bcl-2-specific siRNAs restore Gemcitabine sensitivity in human pancreatic cancer cells
por: Okamoto, Kinya, et al.
Publicado: (2007)

An RFC4/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness
por: Liu, Lei, et al.
Publicado: (2021)

Notch3 regulates ferroptosis via ROS‐induced lipid peroxidation in NSCLC cells
por: Li, Zhikang, et al.
Publicado: (2022)

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
por: Caiola, Elisa, et al.
Publicado: (2018)

Overexpressed FOXM1 collaborates with MMB to increase WEE1 inhibitor sensitivity in NSCLC
por: Tan, Jian, et al.
Publicado: (2023)

Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling
por: Zhang, Zhengle, et al.
Publicado: (2018)

NOTCH3 missense mutations as predictor of long-term response to gemcitabine in a patient with epithelioid hemangioendothelioma
por: Schmidt, Moritz, et al.
Publicado: (2023)

A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel
por: Mato-Berciano, Ana, et al.
Publicado: (2017)

Engineering of an enhanced synthetic Notch receptor by reducing ligand-independent activation
por: Yang, Zi-jie, et al.
Publicado: (2020)

Discovery of a pyrrole-pyridinimidazole derivative as novel SIRT6 inhibitor for sensitizing pancreatic cancer to gemcitabine
por: Song, Nannan, et al.
Publicado: (2023)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Reck-Notch1 Signaling Mediates miR-221/222 Regulation of Lung Cancer Stem Cells in NSCLC
por: Guo, Yuefan, et al.
Publicado: (2021)

LINC01714 Enhances Gemcitabine Sensitivity by Modulating FOXO3 Phosphorylation in Cholangiocarcinoma
por: Shen, Sheng, et al.
Publicado: (2019)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
por: Lin, Chien-Chung, et al.
Publicado: (2021)

Gold Nanoparticles sensitize pancreatic cancer cells to gemcitabine
por: Huai, Yanyan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m7mhrb4ukskujaog2pm0uvc5ql